TR201009398A2 - Fiziksel özellikleri geliştirilmiş tablet formülasyonları - Google Patents

Fiziksel özellikleri geliştirilmiş tablet formülasyonları

Info

Publication number
TR201009398A2
TR201009398A2 TR2010/09398A TR201009398A TR201009398A2 TR 201009398 A2 TR201009398 A2 TR 201009398A2 TR 2010/09398 A TR2010/09398 A TR 2010/09398A TR 201009398 A TR201009398 A TR 201009398A TR 201009398 A2 TR201009398 A2 TR 201009398A2
Authority
TR
Turkey
Prior art keywords
physical properties
improved physical
tablet formulations
locotriene
antihistaminic
Prior art date
Application number
TR2010/09398A
Other languages
English (en)
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09398A priority Critical patent/TR201009398A2/xx
Priority to PCT/TR2011/000243 priority patent/WO2012064301A2/fr
Priority to PCT/TR2011/000247 priority patent/WO2012064305A2/fr
Publication of TR201009398A2 publication Critical patent/TR201009398A2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TR2010/09398A 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları TR201009398A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (tr) 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları
PCT/TR2011/000243 WO2012064301A2 (fr) 2010-11-11 2011-11-03 Formulations de comprimés aux propriétés physiques améliorées
PCT/TR2011/000247 WO2012064305A2 (fr) 2010-11-11 2011-11-03 Formulations ayant des caractéristiques physiques améliorées

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (tr) 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları

Publications (1)

Publication Number Publication Date
TR201009398A2 true TR201009398A2 (tr) 2012-05-21

Family

ID=45446164

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09398A TR201009398A2 (tr) 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları

Country Status (2)

Country Link
TR (1) TR201009398A2 (fr)
WO (2) WO2012064305A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
RU2677649C2 (ru) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Фармацевтические композиции монтелукаста и левоцетиризина
CA2901413A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement de la vascularite
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
WO2015163978A1 (fr) 2014-04-25 2015-10-29 R.P. Scherer Technologies, Llc Solution stable de montélukast
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
EP3222279B1 (fr) 2016-03-21 2021-11-17 Invest Bielany Spolka z ograniczona odpowiedzialnoscia Préparation pharmaceutique orale de montélukast et de lévocétirizine et procédé pour sa production
WO2017210417A1 (fr) * 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Lévocétirizine et montélukast dans le traitement d'états pathologiques médiés par une exposition à des rayonnements
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
MX2018011699A (es) * 2018-09-26 2019-07-24 Federico Amezcua Amezcua Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
MA54707A (fr) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes
EP4153178A4 (fr) 2020-05-19 2024-06-05 Irr, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes
JP2024514989A (ja) * 2021-10-21 2024-04-03 ハン ファ ファーマ カンパニー、リミテッド モンテルカストまたはその薬学的に許容可能な塩、及びレボセチリジンまたはその薬学的に許容可能な塩を含有する、安定性が改善されたフィルムコーティング錠剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (fi) 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
ES2122042T3 (es) 1992-09-24 1998-12-16 Sepracor Inc Tratamiento de rinitis alergica y asma que emplea (-)cetirizina.
AU2003264859A1 (en) 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
PT1976522E (pt) * 2005-12-30 2013-09-09 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica contendo montelucaste
CA2635841A1 (fr) 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Formulations pharmaceutiques stables de montelukast sodique
US20090124657A1 (en) * 2007-08-14 2009-05-14 Ramesh Kappala Pharmaceutical compositions comprising montelukast
WO2009122187A2 (fr) * 2008-04-03 2009-10-08 Cipla Limited Composition pharmaceutique
WO2010107404A1 (fr) * 2009-03-16 2010-09-23 Mahmut Bilgic Combinaisons pharmaceutiques stables

Also Published As

Publication number Publication date
WO2012064305A3 (fr) 2012-08-09
WO2012064301A2 (fr) 2012-05-18
WO2012064305A2 (fr) 2012-05-18
WO2012064301A3 (fr) 2012-07-19

Similar Documents

Publication Publication Date Title
TR201009398A2 (tr) Fiziksel özellikleri geliştirilmiş tablet formülasyonları
PH12014502577A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
MX366018B (es) Composiciones de células t deficientes del receptor de células t.
IL234508B (en) Inhalation of nitric oxide for treating respiratory diseases
IT1401979B1 (it) Dispositivo biomedico per la riabilitazione robotizzata dell'arto superiore umano, particolarmente per la riabilitazione neuromotoria dell'articolazione della spalla e del gomito.
WO2015031808A3 (fr) Procédés de diagnostic et compositions pour le traitement d'un glioblastome
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
DK2800581T3 (da) Fremgangsmåder til behandling af adfærdssymptomer på neurologiske og mentale forstyrrelser
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
EA201500314A1 (ru) Лекарственные формы энзалутамида
LT4104824T (lt) Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą
HK1207304A1 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
CU24133B1 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
DK3065764T6 (da) Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling
PT2501234T (pt) Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
EP2990017A4 (fr) Dispositif portable pouvant traiter la maladie de meniere et des symptômes similaires a celle-ci
IL312551A (en) Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
BR112012030331A2 (pt) isoformas de neuregulin, polipeptídeos de neuregulin, e usos dos mesmos
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
PL3678692T3 (pl) Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии
CO6592047A2 (es) Formulación tópica oftálmica de péptidos